Detailseite
Transportproteine des Hepatozyten: Funktionelle Konsequenzen von Polymorphismen und Haplotypen in Transportergenen
Antragsteller
Professor Dr. Jörg König
Fachliche Zuordnung
Pharmakologie
Förderung
Förderung von 2001 bis 2009
Projektkennung
Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 5340136
Erstellungsjahr
2008
Zusammenfassung der Projektergebnisse
Keine Zusammenfassung vorhanden
Projektbezogene Publikationen (Auswahl)
-
Expression and Immunolocalization of the Multidrug Resistance Proteins, MRP1 – MRP6 (ABCC1 – ABCC6), in Human Brain. Neuroscience, 129, 349-360 (2004)
Nies, A.T., Jedlitschky, G., König, J., Herold-Mende, C., Steiner, H.-H., Schmitt, H.-P., und Keppler, D
-
ABCC Efflux Pumps and OATP Uptake Transporters in Human Gliomas and the Blood-Tumor Barrier. Cancer Res. 65, 11419-11428 (2005)
Bronger, H., König, J., Kopplow, K., Steiner H.-H., Herold-Mende, C., Keppler, D., und Nies, A.T.
-
Expression and Localization of Multidrug Resistance Protein (ABCC) Family Members in Pancreatic Carcinoma. Int. J. Cancer, 115, 359-367 (2005)
König, J., Hartel, M., Nies A.T., Martignoni, M.E., Guo, J., Büchler, M.W., Friess, H., und Keppler, D.
-
Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-transfected Cells. Mol. Pharmacol., 68, 1031-1038 (2005)
Kopplow, K., Letschert, K., König, J., Walter B., und Keppler, D.
-
ATP-binding Cassette Transporters in the Heart. Trends Cardiovasc. Med., 16, 7-15 (2006)
Solbach, T., König, J., Fromm, M.F., und Zolk, O.
-
Effect of SLCO1B1 Polymorphism on Induction of CYP3A4 by Rifampicin. Pharmacogenet Genomics 16, 565-568 (2006)
Niemi, M., Kivistö, K.T., Diczfalusy, U., Bodin, K., Bertilsson, L., Fromm, M.F., und Eichelbaum, M.
-
Pharmacogenomics of human OATP Transporters. Naunyn-Schmiedeberg´s Arch. Pharmacol., 372, 432-443 (2006)
König, J., Seithel, A., Gradhand, U., und Fromm, M.F.
-
Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans. Pharmacol. Ther. 81:362-370 (2007)
Glaeser, H., Bailey D.G., Dresser, G.K., Gregor, J.C., Schwarz, U.I., MaGrath, J.S., Jolicoer, E., Lee, W., Leake, B.F., Tirona, R.G., and Kim, R.B.
-
Role of P-glycoprotein Inhibition for Drug Interactions: Evidence from in vitro and Pharmacoepidemiologic Studies. Clin. Pharmacokinet., 46, 1039-1049 (2007)
Eberl, S., Renner, B., Neubert, A., Reisig, M., Bachmakov, I., König, J., Dörje, F., Mürdter, T.M., Ackermann, A., Dormann, H., Gassmann, K.G., Hahn, E.G., Schölmerich, J., Brune. K., und Fromm, M.F.
-
The Influence of Macrolid Antibiotics of the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3. Drug Metab. Disp., 35, 779-786 (2007)
Seithel, A., Eberl, S., Singer, K., Auge, D., Heinkele, G., Wolf, N.B., Dörje, F., Fromm, M.F., und König, J.
-
10th European Regional Meeting (Wien 2008) The Role of Lysine- and Arginine-Residues for the Transport Activity of OATP1B3. Drug Metab. Rev. 40, Suppl. I: 36 (2008)
Hartmut Gläser
-
Disposition of Ezetimibe is Influenced by Polymorphisms of the Hepatic Uptake Carrier OATP1B1. Pharmacogenet Genomics, 18:559-568 (2008)
Oswald, S., König, J., Lütjohann, D., Giessmann, T., Kroemer, H.K., Rimmbach, C., Rosskopf, D., Fromm, M.F., und Siegmund, W.
-
Interaction of Oral Antidiabetic Drugs with Hepatic Uptake Transporters: Focus on OATPs and OCT1. Diabetes, 57:1463-1469 (2008)
Bachmakov, I., Glaeser, H., Fromm, M.F., und König, J.
-
Non-synonymous Polymorphisms in the Human SLCO1B1 gene: an in vitro Analysis of SNP c.1929A>C. Mol. Genet. Genomics, 279, 149-157 (2008)
Seithel, A., Klein, K., Zanger, U.M., Fromm, M.F. und König, J.
-
The functional Consequences of Genetic Variations in Transporter Genes Encoding Human Organic Anion Transporting Polypeptide Family Members. Expert Opin. Drug Metab. Toxicol., 4, 51-64 (2008)
Seithel, A., Glaeser, H., Fromm, M.F., und König, J.
-
Transporters and Drugs – an Overview. In: R. Vaz and T. Klabunde (Eds.), Antitargets – Prediciton and Prevention of Drug Side Effects, Vol 38, 341-366 (2008)
Glaeser, H., Fromm, M.F., und König, J.
-
Relevance of Conserved Lysine and Arginine residues located in transmembrane helices for the transport activity of OATP1B3. Mol. Pharmacol.
Glaeser, H., Mandery, K., Fromm, M.F., und König, J.